Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2010-11-22
2011-10-04
Duffy, Patricia A (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S244100
Reexamination Certificate
active
08029798
ABSTRACT:
The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier.
REFERENCES:
patent: 4372883 (1983-02-01), Matuhashi et al.
patent: 5623057 (1997-04-01), Marburg et al.
patent: 0 497 525 (1992-08-01), None
patent: 88/00056 (1998-01-01), None
patent: 00/56360 (2000-09-01), None
patent: 03/051392 (2003-06-01), None
Klein, “Pneumococcal Conjugate Vaccines: Review and Update”, Microbial Drug Resistance, 1995, 49-58, 1(1), Mary Ann Liebert, Inc.
Fattom, et al., “Overload of Homologous Carrier Protein at the Site of Injection Might Cause a Reduced Immunogenicity of Capsular Polysaccharide Conjugate Vaccines”, Abstracts of the 36th ICAAC, 160, Nabi-Rockville, USA.
Ahman, et al, “Immunogenicity of Octavalent Pneumococcal (Pnc) Conjugate Vaccines (PncD. PncT) in Finnish Infants”, Abstracts of the 36th ICAAC, 1 page, Tuesday, Session 61, Nabi-Rockville, USA.
Dagan, et al., “Reduction of Antibody Response to an 11-Valent Pneumococcal Vaccine Coadministered With a Vaccine Containing Accellular Pertussis Components”, Infection and Immunity, Sep. 2004,, 5383-5391, 72(9), American Society for Microbiology.
Ortqvist, et al., “Pneumococcal Capsular Polysaccharide Vaccine (PCPV) for Prevention of Pneumonia in Middle-Aged and Elderly Persons: A Prospective, Randomized, Placebo-Controlled Multicenter-Trial”, Abstracts of the 36th ICAAC, 1 page, Tuesday Session 61, Nabi-Rockville, USA.
Holmes, et al., “Immunogenicity of Four Haemophilus Influenzae Tybe b Conjugate Vaccines in 17- to 19-month-old Children”, The Journal of Pediatrics, Mar. 1991, 364-371, 118(3), St. Louis, USA.
“Pertussis Vaccines/Pneumococcal Vaccines”, Martindale: The Extra Pharmacopoeia, 1996, 11 pages, Royal Pharmaceutical Society.
Olander, et al., “Booster Response to the Tetanus and Diphtheria Toxoid Carriers of 11-Valent Pneumococcal Conjugate Vaccine in Adults and Toddlers”, Vaccine 20, 2002, 336-341, Elsevier.
Puumalainen, et al., “Greater Antibody Responses to an Eleven Valent Mixed Carrier Diphtheria- or Tetanus-Conjugated Pneumococcal Vaccine in Filipino Than in Finnish or Israeli Infants”, The Pediatric Infectious Disease Journal, Feb. 2003, 141-149, 22(2).
Sigurdardottir, et al., “Immune Response to Octavalent Diphtheria- and Tetanus-Conjugated Pneumococcal Vaccines is Serotype- and Carrier-Specific: The Choice for a Mixed Carrier Vaccine”, The Pediatric Infectious Disease Journal, 2002, 548-554, 21(6).
“Board Accepts ‘Reward’ Approach to Funding Must Be Postponed”, GAVI Immunization Focus, Mar. 2002, 1-8.
Eick, et al., “Safety and Immunogenicity of Two Octavalent Pneumococcal Conjugate Vaccines in American Indian Infants”, Vaccine 22, 2004, 1260-1264, Elsevier.
Nurkka, et al., “Serum and Salivary Anti-Capsular Antibodies in Infants and Children Vaccinated With Octavalent Pneumococcal Conjugate Vaccines, PncD and PncT”, Vaccine 20, 2002, 194-201, Elsevier.
Schutze, Marie-Paule, et al., “Carrier-Induced Epitopic Suppression, A Major Issue for Future Synthetic Vaccines,” The Jounal of Immunology, Oct. 1985, pp. 2319-2322, vol. 135, No. 4, The American Association of Immunologists.
Sood, Ramesh K., et al., “Capsular Polysaccharide-Protein Conjugate Vaccines,” Research Focus Reviews, DDT, Sep. 1996, pp. 381-387, vol. 1, No. 9, Elsevier Science Ltd.
Sarnaik, Sharada MD, et al., “Studies on Pneumococcus Vaccine Alone or Mixed With DTP and on Pneumococcus Type 6B and Haemophilis Influenzae Type b Capsular Polysaccharide-Tetanus Toxoid Conjugates in Two Five-Year-Old Children With Sickle Cell Anemia,” 1990, pp. 181-186, vol. 9, No. 3, Williams &.
Andrew, P.W., et al., “Pneumococcal Vaccines,” Freer et al. (Eds.), Bacterial Protein Toxins, Zbl. Bakt. Suppl. 24, 1994, pp. 453-466, Gustave Fischer, Stuttgart, Jena, New York.
Steinhoff, M.C., et al., “A Randomized Comparison of Three BivalentStreptococcus pneumoniaeGlycoprotein Conjugate Vaccines in Young Children: Effect of Polysaccharide Size and Linkage Characteristics,” Pediatr Infect Dis J, 1994, pp. 368-372, vol. 13, No. 5, Williams & Wilkins.
Daum, R.S., Immunogenicity of S. Pneumonlae Oligo-and Polysaccharide-CRM 197 Conjugate Vaccine in Healthy US Infants, Presented at the 35th Intersc Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G65, p. 170.
O'Brien, K.L., et al., “Immunologic Priming of Young Children by Pneumococcal Glycoprotein Conjugate, But Not Polysaccharide, Vaccines,” Pediatr Infect Dis J, 1996, pp. 425-430, vol. 15, No. 5, Williams & Wilkins.
Ahman, Heidi, et al., “PentavalentPneumococcal oligosaccharideConjugate Vaccine PncCRM is Well-Tolerated and Able to Induce an Antibody Response in Infants,” Pediatr Infect Dis J, 1996, pp. 134-139, vol. 15, No. 2, Williams & Wilkins.
Infectious Diseases, 1081-1086.
Shelly, Mark, A., et al., “Comparison of Pneumococcal Polysaccharide and CRM 197 ConjugatedPneumococcal oligosaccharideVaccines in Young and Elderly Adults,” Infection and Immunity, Jan. 1997, pp. 242-247, vol. 65, No. 1, American Society for Microbiology.
Kayhty, Helena, et al., “Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children,” JID, Nov. 1995, pp. 1273-1278.
Dagan, Ron, “Reduction of Nasopharyngeal Carriage ofPneumococciDuring the Second Year of Life by a Heptavalent Conjugate Pneumococcal Vaccine,” The Journal of Infectious Diseases, 1996, pp. 1271-1278, The University of Chicago.
Dagan, Ron, et al., “Reduction ofPneumococcal nasopharyngealCarriage in Early Infancy After Immunization withTetravalent pneumococcalVaccines Conjugated to Either Tetanus Toxoid or Diphtheria Toxoid,” Pediatr Infect. Dis. J., 1997, pp. 1060-1064, vol. 16, No. 11, Williams & Wilkins.
Lindberg, A. A., “Recent Trends in the Developments of Bacterial Vaccines,” Brown F. (ed): New Approaches to Stabilisation of Vaccines Potency. Dev Biol. Stand. Basel, Karger, 1996, pp. 59-71, vol. 87.
Nieminen T., et al., “Mucosal and Serum Immune Response toTetravalent pneumococcal(SPn) Conjugate Vaccines (SPnD and SPnT) in Adults,” National Public Health Institute, Helsinki, Finland. Presented at the 34th Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstract G89, p. 236.
Portier, H., et al., “Serum Antibody Response to aTetravalent pneumococcal-Tetanus Toxoid Conjugate (PnTt) Vaccine in Adult Volunteers,” Presented at the 34th Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstract G91, p. 236.
Keyserling, Harry, et al., “Immunogenicity of Pneumococcal Type 14 Conjugate Vaccine in Infants,” Infectious D., Abstract 1087, p. 184A.
Kennedy, Donald, et al., “Immunologic Response to Licensed Pneumococcal Polysaccharide Vaccine (PS) in Infants Primed With HeptavalentStreptococcus pneumoniasConjugated Vaccine (CV),” Presented at the 34th Intersc. Conf. Antimicrob. Agents in Cehmotherapy, Orlando Abstract G90 p. 236, Session 114, Saint. Louis University Health Sciences Center, St. Louis, MO.
Greenberg, David, P., et al., “Factors Influencing the Immunogenicity of a Pneumococcal Conjugate Vaccine in Infants,” Infectious D., 709., Pediatric Research: Apr. 1997—vol. 41—Issue 4, Part 2—p. 121; 1997 Abstracts The American Pediatric Society and The Society for Pediatric Research.
Kennedy, Donald, et al., “Immunologic Response of 12-18 Month Old
Duffy Patricia A
McDonnell Boehnen & Hulbert & Berghoff LLP
Sanofi Pasteur S.A.
LandOfFree
Multivalent vaccine composition with mixed carrier does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent vaccine composition with mixed carrier, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent vaccine composition with mixed carrier will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4302884